Pershing Edward 4

What Happened

• Pershing Edward, CEO and director of Provectus Biopharmaceuticals (PVCT), purchased 34,940 shares of Series D‑1 Convertible Preferred Stock in a private transaction on February 9, 2026. The reported price was $2.86 per preferred share, for a total cash outlay of $99,998. The filing reports this as a purchase (transaction code P).

Key Details

• Transaction date and price: 2026-02-09, 34,940 Series D‑1 preferred shares at $2.86 each, total $99,998.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes from the filing:
  • F1: The purchase was of Series D‑1 Preferred Stock in a private transaction.
  • F2: Each Series D‑1 preferred share is convertible into 10 shares of the issuer’s common stock.
  • F3: The Series D‑1 preferred will automatically convert into common stock on December 31, 2028, unless converted earlier under its Certificate of Designation.
• Timeliness: The form was filed on Feb 11, 2026, for a Feb 9 transaction—appears to be filed within the standard Form 4 reporting window.

Context

• This was a direct purchase of convertible preferred stock (a derivative security) rather than an open‑market common‑stock buy. Each preferred share converts into 10 common shares, so the 34,940 preferred shares represent the right to 349,400 common shares upon conversion (automatic on 12/31/2028 unless converted earlier). Purchases by insiders are often of interest to investors because they increase the insider’s economic stake, but the filing itself does not state the insider’s motivation.